Fig. 6: Schematic model of how vitamin D promotes the cisplatin sensitivity of oral cancer by inhibiting the LCN2-RPS3-NF-κB pathway. | Cell Death & Disease

Fig. 6: Schematic model of how vitamin D promotes the cisplatin sensitivity of oral cancer by inhibiting the LCN2-RPS3-NF-κB pathway.

From: Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3

Fig. 6

In OSCC cells, vitamin D promoted LCN2 promoter methylation to inhibit LCN2 protein expression, which reduced LCN2-RPS3 binding and thus reduced RPS3-NF-κB binding. The formation of the NF-κB complex ultimately reduced the activation of NF-κB, increasing the chemotherapeutic sensitivity of the tumour to cisplatin.

Back to article page